All Posts By

Smartkarma Daily Briefs

Daily Brief Japan: Nomura Research Institute Ltd, Kakaku.com Inc, Electric Power Development C and more

By | Daily Briefs, Japan

In today’s briefing:

  • Nomura Research Institute (4307) Large Secondary Offering – Demand Profile and Index Implications
  • Kakaku.com Inc.: A Deep-Dive View
  • 2023 High Conviction: J-Power Stands Out As Japan Goes Carbon Neutral
  • Nomura Research Placement – Somewhat Well Flagged, past Deals Have Done Well but Momentum Is Weak

Nomura Research Institute (4307) Large Secondary Offering – Demand Profile and Index Implications

By Travis Lundy

  • On Friday, Nomura Research Institute Ltd (4307 JP) announced that Jafco Co Ltd (8595 JP) and Nomura Holdings (8604 JP) would each sell NRI shares in a Secondary Offering.
  • JAFCO is selling to fund a giant buyback. Nomura is selling to round out the offering size. The total is 37mm shares plus greenshoe of 5.5mm shares. 
  • At Friday’s price that is ~¥140bn (including greenshoe), 7% of shares out, 10% of float, and about 25% of Real World Float. There are index implications.

Kakaku.com Inc.: A Deep-Dive View

By Steven Chen

  • Kakaku.com Inc. can be a rare species among listed companies in Japan;
  • We had multiple email exchanges and meetings with the management team for a deep-dive view covering corporate cultural, management style, capital allocation, business model, and competitive strength.
  • We would wait for a 20%-30% pullback in the share price before looking to add to our position but would certainly remain reluctant to sell any share that we own.

2023 High Conviction: J-Power Stands Out As Japan Goes Carbon Neutral

By Oshadhi Kumarasiri

  • Operating under the brand name J-Power, Electric Power Development C (9513 JP) is leading Japan’s efforts to make carbon dioxide-free electricity by 2050.
  • The company’s investments in gasification and carbon dioxide separation technology and carbon dioxide-free hydrogen generation from coal are close to commercialisation.
  • With the technology to serve other power producers to develop their own environmentally-friendly power projects, J-Power could turn into a global-leader in the power generation space in the next decade.

Nomura Research Placement – Somewhat Well Flagged, past Deals Have Done Well but Momentum Is Weak

By Sumeet Singh


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief China: Zhejiang Longsheng Group Co.,, Beijing-Shanghai High Speed Railway-A, CGN New Energy Holdings, Meituan, Yashili International Holdings, Growatt Technology, BeiGene Ltd, China Gas Holdings, Indika Energy, Bosideng International Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • CSI 500 Index Rebalance: 50 Changes a Side Leads to 12%+ One-Way Turnover
  • SSE180/​​​SSE380 Index Rebalance: Changes & Potential MSCI/FTSE Inclusions & Exclusions
  • CGN New Energy Holdings: Character Building
  • Meituan: New Reporting Structure Conceals Loss-Making Businesses and Hard to Assess Core Businesses
  • Merger Arb Mondays (28 Nov) – Yashili, Perpetual/Pendal, Nitro, Warrego, Chip Eng Seng
  • Growatt Technology IPO: Valuation First Look
  • BeiGene (6160.HK/BGNE.US) 22Q3 – The Price of Being an “Outlier”
  • China Gas Holdings (384 HK): Still Not Meeting Expectations
  • Morning Views Asia: Indika Energy, Meituan
  • Bosideng (3998 HK): Decent Result Distorted by Impairment Losses

CSI 500 Index Rebalance: 50 Changes a Side Leads to 12%+ One-Way Turnover

By Brian Freitas

  • There are 50 changes a side for the CSI 500 Index at the upcoming rebalance that will be implemented at the close of trading on 9 December.
  • One-Way turnover at the rebalance is estimated at 12.64% leading to a one-way trade of CNY 9.3bn. The Materials, Information Technology and Consumer Discretionary sectors are net gainers.
  • 9 adds to the CSI 500 Index are deletes from the CSI 300 Index while 7 deletes from the CSI 500 Index are adds to the CSI 300 Index.

SSE180/​​​SSE380 Index Rebalance: Changes & Potential MSCI/FTSE Inclusions & Exclusions

By Brian Freitas

  • There are 18 changes to the SSE180 Index and 38 changes to the SSE380 Index that will be implemented at the close of trading on 9 December.
  • There will be 10 deletions from the MSCI Standard Index and 26 deletions from the FTSE All-World/All-Cap indices at the close on 9 December.
  • Currently, 8 stocks meet the threshold/are close for inclusion in the MSCI China Index while there are 21 stocks that meet the threshold for inclusion in the FTSE All-World/All-Cap indices.

CGN New Energy Holdings: Character Building

By David Blennerhassett

  • A “valuation system with Chinese characteristics” has the media, ostensibly, discussing whether this implies a premium for SOEs and companies aligned with national goals.
  • In early 2020, SOE-backed clean energy play CGN New Energy Holdings (1811 HK) was subject to a potential privatisation from its parent; but it failed to materialise. 
  • During the 14th and 15th Five-Year Plans (2021-30) period, China’s installed capacity for wind and solar power is expected double.

Meituan: New Reporting Structure Conceals Loss-Making Businesses and Hard to Assess Core Businesses

By Shifara Samsudeen, ACMA, CGMA

  • Meituan reported 3Q2022 results. Revenue increased 28.2% YoY to RMB62.6bn (vs consensus RMB62.3bn) while reported an OP of RMB988m (consensus OP loss of RMB935m) for the first time since 3Q2019.
  • However, on adjusted basis, Meituan made an adjusted operating loss of RMB1.1bn (1.7% of revenue) of revenues compared to an adjusted operating loss of RMB7.7bn (15.1% of revenue) in 3Q2022.
  • Tencent announced that it will distribute majority of its shareholding on Meituan (3690 HK) to its shareholders in dividends and Naspers is expected to sell the Meituan Shares it receives from Tencent.

Merger Arb Mondays (28 Nov) – Yashili, Perpetual/Pendal, Nitro, Warrego, Chip Eng Seng

By Arun George


Growatt Technology IPO: Valuation First Look

By Arun George


BeiGene (6160.HK/BGNE.US) 22Q3 – The Price of Being an “Outlier”

By Xinyao (Criss) Wang

  • Our forecast of the total peak sales of BRUKINSA, tislelizumab and the rest commercialized products is about RMB10 billion, which is not enough for BeiGene to turn losses into profits. 
  • BeiGene has the highest R&D/academic ability among domestic pharmaceutical enterprises,but BeiGene cannot be assessed according to the standards of Chinese pharmaceutical enterprises due to its fundamentally different cost structure/breakeven point.
  • The current market value has already priced in the success of TIGIT project to some extent. In other words, the upward elasticity may be limited. But BeiGene deserves long-term follow.

China Gas Holdings (384 HK): Still Not Meeting Expectations

By Osbert Tang, CFA

  • While China Gas Holdings (384 HK) expects better gas dollar margin HoH, there are still high profit uncertainties and its full-year operational guidance does not look exciting.
  • The expectation of flat to 10% YoY decline in new residential household connections is not encouraging. With 1H FY23 profit only amounted to 42% of consensus, we see downgrade risks.
  • Despite achieving positive free cash flow, its high gearing of 69.9% (+4pp HoH) is still very stretched relative to peers. We prefer Kunlun Energy (135 HK).

Morning Views Asia: Indika Energy, Meituan

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Bosideng (3998 HK): Decent Result Distorted by Impairment Losses

By Osbert Tang, CFA

  • Amid the challenging market, Bosideng International Holdings (3998 HK)‘s 15% growth in 1H FY23 profit is decent. Excluding impairments, operating profit would have grown by 31.3%.
  • It expects FY23 gross margin to expand and further store optimisation to enhance operating margin. The introduction of highly successful ultralight down jackets is an added driver.
  • With 32% increase in online branded apparel sales, the channel will be Bosideng’s key growth impetus. For “double-11”, sales have outperformed peers significantly, showcasing its product strengths.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief ECM: ECM Weekly (27th Nov 2022) – Growatt and more

By | Daily Briefs, ECM

In today’s briefing:

  • ECM Weekly (27th Nov 2022) – Growatt, Lygend, Sunshine Ins, Weilong, DPC, Daiei, Skymark, GoTo

ECM Weekly (27th Nov 2022) – Growatt, Lygend, Sunshine Ins, Weilong, DPC, Daiei, Skymark, GoTo

By Sumeet Singh

  • Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
  • On the IPO front, things are picking up again going into the year end.
  • There were no large placement or blocks this week, although prior lockup linked blocks kept flowing through.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Technical Analysis: Meituan 105 Buy Support and more

By | Daily Briefs, Technical Analysis

In today’s briefing:

  • Meituan 105 Buy Support

Meituan 105 Buy Support

By Thomas Schroeder

  • Meituan (3690 HK) has some big resistance hurdles to overcome and will act as tactical sell levels to seek out the 105 buy zone.
  • A tactical bounce back to 165 is on the cards with 168/75 the high degree sell barrier. Secondary trendline resistance rests near 185 as the bigger sell zone.
  • The bearish rising wedge stands out as the dominant force. The support break warns of fallout after a bounce attempt back to 168. A weak bounce would turn near 160.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Event-Driven: CSI300 Index Rebalance: The Surprises Could Outperform and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • CSI300 Index Rebalance: The Surprises Could Outperform
  • STAR50 Index Rebalance: Adds Outperform Deletes in the Last Week
  • Index Rebalance & ETF Flow Recap: NKY, FTSE AW/CH50/TW50/Div+, Sensex, KLCI, SET50, HSTECH, Huarong
  • SSE50 Index Rebalance: In Line with Forecasts; Trades Performing Well
  • JAFCO (8595) Yields to Murakami Greenmail – Big Asset Sale, Big Buyback
  • EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades
  • Socionext (6526 JP) TOPIX Inclusion – Great Performer Deserves Profit-Taking
  • Last Week in Event SPACE: Meituan, Link Admin/Pexa, DTAC/True, Medley
  • (Mostly) Asia-Pac Weekly Risk Arb Wrap: Chip Eng Seng, Mori Trust, Pendal/Pendal, DTAC/True
  • Hong Kong CEO & Director Dealings (25 Nov): JL Mag Rare Earth, Joinn Laboratories, Hopefluent

CSI300 Index Rebalance: The Surprises Could Outperform

By Brian Freitas

  • There are 15 changes for the Shanghai Shenzhen CSI 300 Index (SHSZ300 INDEX) at the upcoming rebalance that will be implemented at the close of trading on 9 December.
  • While most of the deletions are in line with forecasts, there are a few differences on the inclusions as the index committee has used its discretion to overlook some names.
  • The Industrials, Materials and Utilities sectors gain index spots at the expense of Health Care, Financials, Consumer Staples and Consumer Discretionary.

STAR50 Index Rebalance: Adds Outperform Deletes in the Last Week

By Brian Freitas

  • The index committee has continued to use a 6-month minimum listing history leading to five changes to the SSE STAR50 (STAR50 INDEX) in December.
  • All changes are in line with our forecasts and there appears to be some pre-positioning over the last week as the deletes have sold off hard.
  • One-Way turnover is estimated at 5.34% and will result in a one-way trade of CNY 3,766m. The estimated impact on the deletes is higher than that on the adds.

Index Rebalance & ETF Flow Recap: NKY, FTSE AW/CH50/TW50/Div+, Sensex, KLCI, SET50, HSTECH, Huarong

By Brian Freitas


SSE50 Index Rebalance: In Line with Forecasts; Trades Performing Well

By Brian Freitas

  • There are 5 changes for the SSE50 Index that will be implemented at the close on 9 December. Passive selling on a few deletions is pretty large.
  • We estimate a one-way turnover of 4.07% at the December rebalance leading to a one-way trade of CNY 3.36bn. Index arb activity could add to the impact on the stocks.
  • The adds have dropped over the last few months while the deletes have moved higher. There could be a reversion of that trend till implementation of the changes.

JAFCO (8595) Yields to Murakami Greenmail – Big Asset Sale, Big Buyback

By Travis Lundy

  • Jafco Co Ltd (8595 JP) has long been known as a “cheap” listed “venture fund” because of its additional large (for it) holding in Nomura Research Institute Ltd (4307 JP).
  • Well-Known Japanese activist Yoshiaki MURAKAMI and his related companies bought a stake. JAFCO responded with a “Policy” (poison pill). Murakami-san ducked and dodged then bought more. Now the exit. 
  • JAFCO will sell its Nomura Research shares in a Secondary Offering, and conduct a large buyback via tender offer. Like other Murakami exits, this one is not designed for you. 

EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades

By Simon Harris

  • Weekly summary of vol changes and moves across Global Markets
  • Analysing ATM volatility and skew changes over the last 5 days
  • We suggest a few trades to take advantage of the implied vol surfaces

Socionext (6526 JP) TOPIX Inclusion – Great Performer Deserves Profit-Taking

By Travis Lundy

  • Socionext (6526 JP) was offered in a range of ¥3,480-3,650, oversubscribed, IPOed at ¥3,650 and closed ¥4200 on Day 1. We can assume that was the “right price.” 
  • Since then, while peers are up 19.8% in the 6 weeks since then, Socionext is up 66%. This year’s biggest Japan IPO has been a big winner.
  • The TOPIX inclusion is on Tuesday at the close. Beware, you don’t know who is in the stock and who is not.

Last Week in Event SPACE: Meituan, Link Admin/Pexa, DTAC/True, Medley

By David Blennerhassett

  • You could imagine people covering their short in Meituan (3690 HK) now. The Hang Seng sell flow on 4 January 2023 is insignificant. But there will be more overhang later. 
  • If you buy Link Administration (LNK AU) outright, you are buying a package of three potential future takeout targets.
  • It’s not certain the scrip terms will continue as stated in the DTAC /True merger, but if they change at all, that would almost certainly require a new shareholder meeting.

(Mostly) Asia-Pac Weekly Risk Arb Wrap: Chip Eng Seng, Mori Trust, Pendal/Pendal, DTAC/True

By David Blennerhassett


Hong Kong CEO & Director Dealings (25 Nov): JL Mag Rare Earth, Joinn Laboratories, Hopefluent

By David Blennerhassett

  • The data in this insight is collated from the “shareholding disclosure” link on the HKEx website.
  • Often there is a corresponding HKEx announcement on the increase – or decrease – in the shareholding by directors. However, such disclosures are by no means an absolute. 
  • These insights may flag those companies where shares have been pledged. Stocks mentioned include JL Mag Rare Earth (6680 HK), Joinn Laboratories (6127 HK), and Hopefluent Group (733 HK).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Thematic (Sector/Industry): Japan Weekly | Quick and Simple Charts and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Japan Weekly | Quick and Simple Charts
  • China Personal Pension System: About Time
  • GEM Weekly (25 Nov 2022): South Korea Rates, Thailand GDP; Samsung Electronics, Ant, Foxconn, Kakao

Japan Weekly | Quick and Simple Charts

By Mark Chadwick

  • With a national holiday in Japan on Wednesday, followed by Thanksgiving in the US, the markets have been relatively quiet this week
  • Maybe traders are too busy watching the World Cup – good news for the stock price of HUB (3030), the English pub-chain
  • We highlight those stocks on our radar that are overbought/sold, cheap and expensive

China Personal Pension System: About Time

By David Blennerhassett

  • China’s banking and insurance regulator announced this week the first batch of insurance products available for consumers to purchase under the country’s newly launched personal pension system.
  • The first seven insurance products are to be provided by four life insurers and two pension insurance companies.
  • Separately, the CBIRC issued final regulations to insurance companies that wish to sell retirement savings products.

GEM Weekly (25 Nov 2022): South Korea Rates, Thailand GDP; Samsung Electronics, Ant, Foxconn, Kakao

By Wium Malan, CFA


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Equity Bottom-Up: Cisarua Mountain Dairy (CMRY IJ) – Fuelled by General Trade and Miss Cimory and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Cisarua Mountain Dairy (CMRY IJ) – Fuelled by General Trade and Miss Cimory
  • Asia Gaming: Despite Macau Woes, Melco Stock Is Too Cheap to Ignore Now
  • China Healthcare Weekly (Nov25)-Wuxi Biologics, Valuation Logic Changed by NRDL, Biotech Model Fails
  • Nitori Retreats from the US but Gets Muscular in Japan and Asia
  • HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth
  • Shionogi & Co (4507 JP): Oral COVID-19 Drug Got Approval; Files Approval for COVID-19 Vaccine

Cisarua Mountain Dairy (CMRY IJ) – Fuelled by General Trade and Miss Cimory

By Angus Mackintosh

  • Cisarua Mountain Dairy (CMRY IJ) remains one of Indonesia’s most interesting high-quality consumer staples companies, with strong brands in both premium dairy products and premium packaged foods. 
  • The company grew total sales by 76% YoY for 9M2022, with dairy products growing 51% YoY and packaged foods by 125% YoY driven by increasing capacity to serve burgeoning demand. 
  • Margins have been impacted by rising raw material prices but powdered milk prices have been falling which should mean margins recover but all the same 9M2022 net profit rose 1.5x.

Asia Gaming: Despite Macau Woes, Melco Stock Is Too Cheap to Ignore Now

By Howard J Klein

  • We calculated the intrinsic value of the stocks is ~30% undervalued at US$6.79 a share.
  • The strong Manila market recovery and planned on time opening of Cyprus property does not seem to be baked into the price at writing.
  • Macau travel bans will keep MLCO dead pooled, but value lies in its assets still at work

China Healthcare Weekly (Nov25)-Wuxi Biologics, Valuation Logic Changed by NRDL, Biotech Model Fails

By Xinyao (Criss) Wang

  • NRDL negotiation has completely changed the pricing method/valuation logic of innovative drugs. Even if price reduction could be milder this year, it’s hard to reverse the shrinking market size/slowing growth.
  • Wuxi Biologics (2269 HK) has successively acquired several factories/production facilities built by domestic biotech companies at low cost. However, we have several concerns.
  • The industry is in the process of understanding and adapting to various changes. The model capital envisioned for biotech to both develop and then commercialize drugs successfully doesn’t work anymore.

Nitori Retreats from the US but Gets Muscular in Japan and Asia

By Michael Causton

  • Nitori is one of few Japanese retailers to brave the US market. The US has beaten Nitori for now and it will instead focus on Japan and Asia. 
  • Nitori’s ability to leverage its efficient supply chains to lower prices will likely lead it to further dominance at home and allow it to invest in the rest of Asia.
  • The company expects pressures on costs to ease in 2023 as the Yen rises but is working on reducing the cost of goods and operations.

HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth

By Tina Banerjee

  • During H1 2022, Yichang HEC Changjiang Pharma (1558 HK) recorded revenue of RMB1.3 billion, representing 540% y/y growth, driven by 1,776% y/y revenue growth from its core product Kewei.
  • With gradual recovery of patient traffic in medical institutions and increasing number of flu cases, Kewei showed a trend of recovery in its sales volume leveraging on its market leadership.
  • HEC Pharma has a comprehensive insulin portfolio, which covers both second and third generations of insulin. With 116 million diabetes patients, China has significant market opportunity for insulin.

Shionogi & Co (4507 JP): Oral COVID-19 Drug Got Approval; Files Approval for COVID-19 Vaccine

By Tina Banerjee

  • On November 22, Shionogi & Co (4507 JP) received emergency regulatory approval for Xocova  in Japan for COVID-19. It is Japan’s first homegrown oral antiviral for SARS-CoV-2 infection.
  • On November 24, Shionogi has filed for manufacturing and sales approval of S-268019, a recombinant protein-based preventive vaccine, for use in priming and booster (third) doses, against COVID-19.
  • Although Shionogi continues to expect ¥110 billion revenue from COVID-19-related products in FY23, the company has raised overall revenue guidance to ¥410 billion from ¥400 billion.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Most Read: Highwealth Construction, Oriental Land, Golden Agri Resources, Semiconductor Manufacturing International Corp (SMIC), Far Eastern New Century, JD Health, Meituan, ENN Natural Gas, Shanghai United Imaging Healthcare, Oci Co Ltd and more

By | Daily Briefs, Most Read

In today’s briefing:

  • FTSE TWSE Taiwan Dividend+ Index Rebalance Preview: 46% One-Way Turnover and US$5bn Two-Way Trade
  • Nikkei 225 Index Rebalance Preview (March): Three Potential Changes & Large Funding Trade
  • FTSE All-World/​​​All-Cap Index Rebalance: Watch Golden Agri-Resources & Delhivery
  • Hang Seng TECH Index Rebalance: Float & Capping Changes
  • FTSE TWSE Taiwan 50 Index Rebalance Preview: Far Eastern Could Replace AUO
  • FTSE China 50 Index Rebalance Preview: JD Health Could Replace Xpeng
  • 2023 High Conviction Ideas: Meituan
  • CSI300 Index Rebalance: The Surprises Could Outperform
  • STAR50 Index Rebalance: Adds Outperform Deletes in the Last Week
  • OCI Spin-Off: Trade Opportunities Post Relisting, Valuations, & Impact on KOSPI 200

FTSE TWSE Taiwan Dividend+ Index Rebalance Preview: 46% One-Way Turnover and US$5bn Two-Way Trade

By Brian Freitas

  • Today is the review cutoff for dividend data and stock prices that will be used to select the inclusions and exclusions as well as for capping of index weights.
  • We see 26 adds and 5 deletes for the index at the December rebalance resulting in one-way turnover of 46% and a one-way trade of TWD 78.1bn (US$2.51bn). 
  • Passive trackers will need to buy over 5 days of ADV on 15 stocks and sell over 5 days of ADV on 19 stocks and this will present trading opportunities.

Nikkei 225 Index Rebalance Preview (March): Three Potential Changes & Large Funding Trade

By Brian Freitas


FTSE All-World/​​​All-Cap Index Rebalance: Watch Golden Agri-Resources & Delhivery

By Brian Freitas


Hang Seng TECH Index Rebalance: Float & Capping Changes

By Brian Freitas

  • As expected, there are no adds or deletes for the Hang Seng Tech Index (HSTECH INDEX) in December. However, there are plenty of capping and float changes to drive flows.
  • The December rebalance is expected to have a one-way turnover of 2.3% resulting in a one-way trade of HK$1.9bn.
  • Short interest is greater than 5% of float on a few stocks and a continued recovering in markets could lead to a squeeze higher.

FTSE TWSE Taiwan 50 Index Rebalance Preview: Far Eastern Could Replace AUO

By Brian Freitas


FTSE China 50 Index Rebalance Preview: JD Health Could Replace Xpeng

By Brian Freitas


2023 High Conviction Ideas: Meituan

By Xin Yu, CFA

  • Meituan is a leading “service e-commerce” platform in China, leveraging technology to connect consumers with merchants.
  • With the gradual re-opening in 2023, core local commerce will deliver better than expected result.
  • Tencent’s distribution of Meituan shares provides a good entry point. 

CSI300 Index Rebalance: The Surprises Could Outperform

By Brian Freitas

  • There are 15 changes for the Shanghai Shenzhen CSI 300 Index (SHSZ300 INDEX) at the upcoming rebalance that will be implemented at the close of trading on 9 December.
  • While most of the deletions are in line with forecasts, there are a few differences on the inclusions as the index committee has used its discretion to overlook some names.
  • The Industrials, Materials and Utilities sectors gain index spots at the expense of Health Care, Financials, Consumer Staples and Consumer Discretionary.

STAR50 Index Rebalance: Adds Outperform Deletes in the Last Week

By Brian Freitas

  • The index committee has continued to use a 6-month minimum listing history leading to five changes to the SSE STAR50 (STAR50 INDEX) in December.
  • All changes are in line with our forecasts and there appears to be some pre-positioning over the last week as the deletes have sold off hard.
  • One-Way turnover is estimated at 5.34% and will result in a one-way trade of CNY 3,766m. The estimated impact on the deletes is higher than that on the adds.

OCI Spin-Off: Trade Opportunities Post Relisting, Valuations, & Impact on KOSPI 200

By Douglas Kim

  • After the spin-off and relisting of holdco/opco shares, we believe that there is a greater probability of OCI Co (opco) shares outperforming OCI Holdings (holdco).
  • However, the degree of outperformance of OCI Co vs OCI Holdings is not likely to be similar to other recent spin-offs such as F&F Co and F&F Holdings.
  • We have a long-term bullish view of OCI over the next one to two years. It is trading at P/E of 3.1x and P/B of 0.6x based 2022 earnings estimates.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Indonesia: Cisarua Mountain Dairy and more

By | Daily Briefs, Indonesia

In today’s briefing:

  • Cisarua Mountain Dairy (CMRY IJ) – Fuelled by General Trade and Miss Cimory

Cisarua Mountain Dairy (CMRY IJ) – Fuelled by General Trade and Miss Cimory

By Angus Mackintosh

  • Cisarua Mountain Dairy (CMRY IJ) remains one of Indonesia’s most interesting high-quality consumer staples companies, with strong brands in both premium dairy products and premium packaged foods. 
  • The company grew total sales by 76% YoY for 9M2022, with dairy products growing 51% YoY and packaged foods by 125% YoY driven by increasing capacity to serve burgeoning demand. 
  • Margins have been impacted by rising raw material prices but powdered milk prices have been falling which should mean margins recover but all the same 9M2022 net profit rose 1.5x.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Singapore: Keppel Corp and more

By | Daily Briefs, Singapore

In today’s briefing:

  • Weekly Deals Digest (27 Nov) – Keppel, Chip Eng Seng, Link Admin, DTAC/True, Growatt, Weilong

Weekly Deals Digest (27 Nov) – Keppel, Chip Eng Seng, Link Admin, DTAC/True, Growatt, Weilong

By Arun George


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars